Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin Clinical Trial

Official title:

Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00186355
• Other study ID #: BMT4IJ
• Secondary ID: 7706312170
• Status: Completed
• Phase: N/A
• First received: September 13, 2005
• Last updated: May 10, 2012
• Start date: October 2003
• Est. completion date: February 2010

Study information

• Verified date: May 2012
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Description:

To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: February 2010
• Est. primary completion date: March 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 75 Years

Eligibility

Inclusion Criteria:- relapsed NHL

Exclusion Criteria:- liver dysfunction

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin

Intervention

Procedure:
• high dose chemo then auto hematopoietic cell transplant

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PCR positivity in peripheral blood cell collections after cyclophosphamide		unknown	No
Secondary	Enrichment of hematopoietic stem cells		unknown	No